Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;39(4):669-671.
doi: 10.1007/s40259-025-00724-2. Epub 2025 Jun 17.

Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review"

Joao Goncalves  1 , Paolo Caliceti  2
Affiliations

Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review"

Joao Goncalves et al. BioDrugs. 2025 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: Editorial support was provided by Megan Thomas, MSc, of Selene Medical Communications (Cheshire, UK), and was funded by Chiesi USA, Inc. Conflicts of Interest: J. Gonçalves has received consulting fees, payment, or honoraria from AstraZeneca, Celltrion, Chiesi, Pfizer, and Samsung Biologics. He has also received grants or other contracts from AstraZeneca and Pfizer. P. Caliceti declares no conflicts of interest. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Availability of Data and Material: Not applicable. Code Availability: Not applicable. Author Contributions: J. Gonçalves and P. Caliceti contributed equally to the development and writing of this letter. Both authors read and approved the final version.

References

    1. Lee CS, Kulkarni Y, Pierre V, Maski M, Wanner C. Adverse impacts of PEGylated protein therapeutics: a targeted literature review. BioDrugs. 2024;38:795–819. - PMC - PubMed
    1. Gonçalves J, Caliceti P. Optimizing pharmacological and immunological properties of therapeutic proteins through PEGylation: investigating key parameters and their impact. Drug Des Dev Ther. 2024;18:5041–62. - PMC - PubMed
    1. Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioeng Transl Med. 2024;9:e10600. - PMC - PubMed
    1. U.S. Food and Drug Administration. Pegasys: highlights of prescribing information [Internet]. 2011 [cited 28 February 2025]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl...
    1. U.S. Food and Drug Administration. Pegintron: highlights of prescribing information [Internet]. 2019 [cited 20 March 2025]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103949s5313lbl...

LinkOut - more resources